Sites of uptake, storage, and metabolism of ['8F] fluorodopamine and excretion of [18F]fluorodopamine and its metabolites were visualized using positron emission tomographic (PET) scanning after intravenous injection of the tracer into anesthetized dogs. Radioactivity was concentrated in the renal pelvis, heart, liver, spleen, salivary glands, and gall bladder.
D ifficulties in direct assessment of sympathetic nervous function have impeded research about the role of the sympathoneural system in stress responses, cardiovascular diseases, and the effects of commonly used drugs. Assessment of cardiac sympathoneural function by analysis of tracer norepinephrine kinetics requires complex, invasive procedures,1 and localized changes in the myocardium are not detectable. Although direct recording of sympathoneural activity can be performed clinically in peripheral nerves,2,3 this has not been possible in other important sympathetically innervated organs such as the heart. Radioactive scanning after injection of [1311] metaiodobenzylguanidine or [1lI]metaiodobenzylguanidine (MIBG) can image adrenergic innervation in the heart4-6; however, the fate of MIBG in sympathetic nerve endings differs from that of endogenous catecholamines because MIBG is not a catecholamine and is not a substrate for the main degradative enzymes that act on catecholamines, monoamine oxidase, and catechol-O-methyltransferase. 7 Moreover, intervals up to hours long can be required for adequate detection and resolution of MIBG-derived radioactivity in cardiac tissue as compared with that in blood.4 M1BG scanning, therefore, seems unsuitable for assessing cardiac sympathetic function by kinetic analyses. 
BLOODSTREAM
We report a method for visualizing sympathetic innervation and function in vivo using positron emission tomography (PET) after systemic intravenous injection of a new imaging agent: [18F]fluorodopamine, a positron-emitting analogue of dopamine. The method is based on the similar neuronal uptake and intraneuronal disposition of fluorocatecholamines and nonfluorinated catecholamines in sympathetic nerve terminals ( Figure 1 ). Chiueh et a18 reported that intravenously administered 6-fluorodopamine is converted to 6-fluoronorepinephrine in sympathetically innervated tissues, demonstrating that 6-fluorodopamine is a substrate for neuronal uptake, vesicular translocation, and ,B-hydroxylation, key steps in the synthesis of the sympathetic neurotransmitter, norepinephrine. The turnover of fluoronorepinephrine was found to be identical to that of [3H] norepinephrine. In rats, we recently observed that at 1 hour after intravenous injection of [3H] dopamine, more than 90% of the tritium contents of left ventricular tissue was in catechols, mainly norepinephrine, whereas less than 2% of the tritium contents of plasma was in catechols.9 Pretreatment with desipramine to block neuronal uptake of catecholamines markedly attenuated accumulation of tritiated dopamine and norepinephrine in cardiac tissue, and pretreatment with reserpine, which blocks translocation of catecholamines from the axonal cytoplasm into storage vesicles, abolished accumulation of tritiated dopamine, tritiated norepinephrine, and total tritium in left ventricular tissue. These results suggested that after intravenous administration, [18F]fluorodopamine would be taken up into sympathetic nerve endings and converted substantially to [18F]fluoronorepinephrine in the vesicles. PET scanning could then be used to visualize sites of sympathetic innervation and obtain information about cardiac sympathetic function. Specifically, the extent of the desipramine-induced decrease in the tissue load of radioactivity could be related to uptake-1 activity, and the turnover of cardiac radioactivity could be related to the turnover of catecholamines in sympathetic vesicles.
To To visualize the accumulation and decline of radioactivity in the heart, liver, gall bladder, kidneys, and spleen, PET scans of the chest and abdomen were obtained after injection of [ In two beagles, sodium nitroprusside (15 mg/500 ml 5% dextrose in water) was infused intravenously beginning approximately 1 hour after the [18F]-6-fluorodopamine injection, the rate progressively increased to decrease mean arterial pressure by approximately 30%.
In one beagle, desipramine (2 mg/kg) was injected intravenously approximately 30 minutes after the [18F]-6 -fluorodopamine injection, and beginning approximately 1 hour after the injection, nitroprusside was infused as previously described to decrease mean arterial pressure by approximately 30%. The nitroprusside infusion was continued for the remainder of the session (approximately 2 hours).
In one beagle, tyramine (15 ,ug/kg/min) was infused intravenously, beginning 60 minutes after injection of ["F]-6-fluorodopamine and continuing for the next 2 hours.
In one beagle, beginning 60 minutes after injection of ['8F]-6-fluorodopamine and continuing for the next 2 hours, trimethaphan was-infused intravenously at a rate (5-25 ,LLg/kg/min) sufficient to maintain about a 30% decrease in mean arterial pressure and abolish reflexive changes in heart rate. Synthesis of [8F]-6-Fluorodopamine 1F-Labeled fluorodopamine was synthesized from 18F-labeled fluorodopa (fluorodihydroxyphenylalanine) by enzymatic decarboxylation of fluorodopa using L-amino-acid-decarboxylase prepared from hog kidneys as previously reported. 16 The enzymatic conversion of dopa to dopamine is known to be very rapid, and we demonstrated that the conversion of fluorodopa to fluorodopamine was also rapid. Positron-emitting 6- 
Data Reduction and Analysis
The PET images were reconstructed with correction for attenuation and for the physical decay of the tracer (the physical half-life of '8F is 1.83 hours), stored on magnetic tape, restored for analysis using a Digital Equipment Corporation (Marlboro, Massachusetts) VAX computer, and analyzed using the Medical Imaging Retrieval, Analysis and Graphics (MIRAGE) software system, developed by the Department of Nuclear Medicine.
In general, two types of data are reported: the images and time-activity curves for regions of interest (ROIs). The images were pictorial representations of cross-sectional tomographic slices of the head, chest, and abdomen and depicted the concentrations (nCi/ ml) of radioactivity in the various body regions.
The time-activity curves related the log of the tissue radioactivity concentration (adjusted for the weight of the animal in kilograms and for the number of millicuries of injected radioactivity [i.e., nCi kg/ml mCi]) to time (in minutes) after injection of the tracer. For plasma or blood, time-activity curves were generated from direct assays of the radioactivity concentrations in aliquots of centrifuged or uncentrifuged arterial blood. Time-activity curves for organ radioactivity were based on circular ROIs that occupied approximately one half of the width of the imaged organ. As indicated in the figures, the resolution of these organs was excellent; the radioactivity generally was maximal at the centers of the ROls in the left ventricular wall, the septum, and the salivary glands, and minimal in the brain, stomach bubble, lungs, and left ventricular cavity.
Biexponential equations of best fit were calculated to determine the effects of the various treatments, using the interactive BLD curve-analysis program. The graphic analyses were performed on a Macintosh II computer using Cricket Graph (Cricket Software, Malvern, Pennsylvania) and on a VAX computer (Digital Equipment Corporation). dopamine ( Figure 3 ). In four untreated dogs, the biologic half-life (tl/2) of blood radioactivity between 1 and 4 minutes after injection was 1.5 minutes. Thereafter, the rate of disappearance of total plasma radioactivity became much slower; for example, 10-60 minutes after the injection, the t1/2 value averaged 32 minutes.
Results

Hemodynamics
In five studies, simultaneous measurements of radioactivity in whole blood and in plasma were obtained. The plasma/blood radioactivity ratio invariably increased progressively during the scanning session, from a minimum value of less than 0.8 to a maximum value of about 1.4 ( Figure 4 ).
PET Scans of Intact Untreated Animals
As shown in Figure 5 , after injection of [18F]-6-fluorodopamine, there was intense positron emission from the renal pelvis, heart, liver, kidneys, spleen, and salivary glands with very little positron emission from the brain, lungs, and skeletal muscle. In the heart, liver, salivary glands, renal pelvis, and spleen, radioactivity concentrations decreased with time, whereas radioactivity accumulated progressively in the gall bladder (Figures 3 and 6 ). The movement of radioactive bile could be followed clearly in a bile duct, with subsequent accumulation of radioactivity in the previously radiolucent gall bladder.
Almost immediate appearance of radioactivity in the renal pelvis demonstrated that a portion of the injected tracer was rapidly filtered and excreted. Thereafter, renal pelvic radioactivity decreased, with tl/2 approximately equal to the t1/2 of the radioactivity in plasma.
After initial distribution, the tissue radioactivity declined biexponentially in the heart, liver, spleen, salivary glands, renal pelvis, and plasma. In four PET studies of intact untreated dogs, myocardial radioactivity during the 3 hours after injection of 
Desipramine Pretreatment
Desipramine pretreatment markedly decreased cardiac positron emission (Figure 3) . In one experiment, the left ventricular myocardium was so poorly visualized that myocardial radioactivity could not be distinguished from radioactivity in the ventricular chamber. Hepatic and plasma radioactivity were increased.
In desipramine-pretreated animals, similar to untreated animals, there was a biexponential decline in myocardial radioactivity after injection of 
Normetanephrine Treatment
In the dog pretreated with normetanephrine, with the infusion continuing at the time of the [18F]-6-fluorodopamine injection, the accumulation and decline of radioactivity in the heart and liver were unaffected. In the heart, the yo values were 3,544 and 1,436 nCikg/mlmCi for the initial rapid and slow late phases, and the tl!2 values were 14 and 128 minutes.
Nitroprusside-Induced Hypotension
Nitroprusside infused at a rate that decreased mean arterial pressure by approximately 30% evoked pronounced reflexive tachycardia. In the dog in which nitroprusside was administered for approximately 1 hour beginning 50 
Tyramine
Tyramine infused intravenously during the interval between 1 and 3 hours after the injection of [18F]-6-fluorodopamine decreased the t112 of myocardial radioactivity by about 61%, from 97 to 38 minutes, compared with the same interval in the same dog when untreated (Figure 9 ).
Trimethaphan
Trimethaphan infused intravenously during the interval of 1-3 hours after the injection of F18F]-6-fluorodopamine prolonged the t1/2 of myocardial radioactivity by 57%, from 97 to 152 minutes, as compared with the same interval in the same dog when untreated ( Figure 9 ).
Discussion
New Sympathetic Neuronal Imaging Agent For at least 3 hours after injection of [18F]-6-fluorodopamine, PET scanning enabled depiction of tissue sites of uptake, retention, and excretion of the amine and its metabolites. In particular, sympathetic nerve terminals were radiolabeled, presumably as a result of amine storage in vesicles, and organs possessing extensive sympathetic innervation, such as the heart, could be imaged with striking clarity, as predicted by previous findings in rats.9
Regional Uptake of ['8F]Fluorodopamine
The most intense uptake of [18F]-6-fluorodopamine was by the heart, followed by the liver, spleen, salivary glands, and chest wall, with virtually no uptake into the brain. These results are consistent with exclusion of catecholamines from brain and with uptake into sympathetically innervated tissues after 
Metabolism and Excretion
Assuming a total renal pelvic volume of 5 ml, it could be estimated that approximately 3% of the injected tracer appeared almost immediately in the renal pelvic urine. Because approximately 25% of the cardiac output at rest is distributed to the kidneys, this estimate is consistent with the finding of Hempel et a124 that about 10% of [14C]dopamine injected directly into the renal artery of dogs was excreted unchanged in the urine. The renal parenchyma contained much less radioactivity than the pelvic urine, indicating that the kidney acted mainly as a conduit for excretion of the tracer and its metabolites. Decreases in plasma radioactivity paralleled decreases in renal pelvic radioactivity, as expected if the excretion was more rapid than renal production of fluorodopamine metabolites and, thereby, determined the later ("gelimination") tl2 of plasma radioactivity.
In The plasma blood radioactivity ratio increased progressively from about 0.9 to about 1.4 during the scanning sessions. Because of this, tissue/plasma radioactivity ratios underestimated tissue/blood ratios, which would be the basis for resolution by PET scanning of tissue sites of uptake and concentration of the tracer. The trend in the plasma/blood radioactivity ratio can be explained by immediate weak binding of the tracer to red blood cell membranes and by relatively efficient exclusion of fluorodopamine metabolites such as homovanillic acid from erythrocytes. In conscious animals, the decline of cardiac radioactivity after injection of radiolabeled norepinephrine seems to be longer and multiphasic compared with isolated organ preparations. For example, Iversen and coworkers29,30 noted a biexponential decline of radioactivity, with half-lives of approximately 6 and 10 hours,29 and 2.5 and 9 hours,30 in rats; and Mueller and Axelrod31 reported an overall tl/2 of 15 hours. There seems to have been no previous study of norepinephrine efflux rates from the hearts of intact dogs, and there are potentially important species differences in the storage or metabolism of catecholamines.32 Because Both these changes after desipramine pretreatment are predicted in a two-compartment kinetic model, including a small extracellular fluid compartment in which the radioactivity equilibrates rapidly with that in blood and a large intracellular compartment, predominantly sympathetic nerve endings, into which radioactivity accumulates from the extracellular fluid pool and is stored. The sum of the radioactivity in the compartments determines the tissue radioactivity detected by PET scanning. Because radioactivity in nerve endings would be lost slowly, prevention of storage accelerates the loss of radioactivity from the tissue as a whole, shortening the tI12 of the rapid early phase. Prevention of neuronal storage also decreases the remaining radioactivity in the tissue as a whole during the slow late phase. This is reflected by a decrease in yo for this phase, whereas the yo for the early phase, representing the rapid entry of radioactivity from the plasma into the extracellular fluid compartment, is not decreased.
Even during uptake-1 blockade, the decline of myocardial radioactivity was biexponential. A similar finding was reported by Bonisch37 for the efflux kinetics of tritiated isoproterenol, which is not a substrate for uptake-1.38 This phenomenon can be explained by the existence of two myocardial extraneuronal pools, that is, an interstitial pool (rapidly equilibrating with plasma) and a smooth muscle cell pool.
The desipramine results suggested that most of the myocardial removal of [18F]-6-fluorodopamine was by uptake into sympathetic nerve endings. The results corresponded well to the approximate 75% decrease in removal of tritiated norepinephrine by the human heart in subjects pretreated with desipramine.' It is possible that during uptake-1 blockade, the extent of downward movement of the yo value of the late portion of the left ventricular myocardial time-activity curve, and the extent of decrease in the early tl2, could provide an index of cardiac uptake-1 activity. Reserpine is, the vesicles are radiolabeled. Because reserpine increases plasma dihydroxyphenylacetic acid levels by approximately 10-fold in conscious rats40 and also increases the extent of deamination of tritiated norepinephrine in the isolated perfused rat heart,41 in reserpinized animals ['8F]-6-fluorodopamine taken up into the axoplasm by uptake-1 probably was metabolized rapidly to [18F]-6-fluorodihydroxyphenylacetic acid, which then diffused rapidly into the bloodstream or underwent extraneuronal conversion to ['8F]-6-fluorohomovanillic acid.9 The effects of reserpine pretreatment on the decline of myocardial radioactivity were consistent with the view that initial uptake of the tracer by the myocardium was generally unimpaired28; however, the ability to retain the radioactivity in the tissue compartment was-markedly decreased. Both the late tl/2 value and the late y-intercept value therefore were decreased.
Rate of Decline of Myocardial Radioactivity
To test the hypothesis that the rate of decline of myocardial radioactivity reflects the turnover of catecholamines in sympathetic vesicles, hypotension was induced by infusing sodium nitroprusside intravenously to increase sympathetic outflow reflexively.'415 The rate of myocardial radioactivity loss was increased by approximately twofold. Conversely, during ganglionic blockade by trimethaphan, the rate of decline of radioactivity was decreased by approximately one half. Manipulations expected to alter cardiac sympathetic outflow therefore induced appropriate changes in the rate of myocardial radioactivity decline.
Changes in the rate of decline of myocardial radioactivity were especially pronounced during infusion of tyramine, which stimulates by displacement the nonexocytotic release of norepinephrine, and after infusion of reserpine, which increases net leakage of vesicular catecholamines into the axoplasm. In the heart, by far the predominant means for removal of circulating catecholamines is by using uptake-1.1 Blockade of nonneuronal uptake (uptake-2) by normetanephrine would not have been expected to alter importantly myocardial uptake or retention of [18F]-6-fluorodopamine, and the present results confirmed this view.
Superior Cervical Ganglionectomy and Cranial Imaging
Low levels of cerebral positron emission were consistent with the known blood-brain barrier for catecholamines. 45 The pattern of cranial PET imaging after injection of [18F]fluorodopamine contrasted with that previously reported after injection of [18F]-6-fluorodopa.46'47 The disposition of systemically administered dopamine, a catecholamine, would be expected to differ substantially from that of systemically administered dopa, a catechol amino acid. First, dopamine does not penetrate the blood-brain barrier, whereas dopa does; second, dopamine is an excellent substrate from neuronal uptake, whereas dopa is not; and third, dopa can be removed from the bloodstream by extraneuronal cells and converted to dopamine by L-aromatic-amino-acid-decarboxylase, whereas dopamine taken up by extraneuronal cells is not converted to norepinephrine because of the localization of dopamine-,B-hydroxylase to noradrenergic neurons and chromaffin cells. Superior cervical ganglionectomy has been used for many years as a preparation for examining sympathetic innervation and function."1-"3 Postganglionic sympathectomy decreases salivary gland uptake of intravenously administered tritiated noradrenaline by more than 90%.12 In the present study, positron emission was decreased on the ganglionectomized side, but only by approximately 50%. Residual positron emission from the ganglionectomized side probably represented nonneuronal uptake of fluorodopamine metabolites from plasma and nonneuronal uptake and metabolism of the labeled amine, with retention of radioactive metabolites as well as amines in the parenchyma and saliva.48 This also would explain why desipramine pretreatment did not grossly affect salivary radioactivity concentrations.10'12, '9 Because ['8F]-6-fluorodopamine administration, rather than [18F]-2-fluorodopamine administration, resulted in a higher ratio for radioactivity from the intact ganglionectomized side, the results confirmed findings in rats that the 6-fluorinated form is more efficiently accumulated and ,B-hydroxylated than the 2-fluoro analogue. 9 
Suitability for Clinical Use
The initial, brief increase in blood pressure and decrease in heart rate after bolus injection of ["F]-6-fluorodopamine was explained by plasma levels of the dopamine analog, which were sufficient to stimulate transiently cardiovascular a-adrenergic recep-1619 postganglionic sympathetic activity. tors49 and to produce vasoconstriction and reflexive bradycardia. The bolus-injected dose of the dopamine analogue corresponded to the approximate dose of dopamine during the first 3 minutes as often infused clinically (5 pig/kg/min). By approximately 5 minutes after the injection, levels of the dopamine analogue decreased to below those that produce detectable hemodynamic or other physiological effects. The magnitude of the brief pressor response after injection of ['5F]-6-fluorodopamine was larger than after injection of [15F]-2-fluorodopamine. Fluorination at the 6-position increases the potency of catecholamines at a-adrenergic receptors. 50 The synthesis used yielded a sterile protein-free radiochemically pure solution of [18F]-6-fluorodopamine in unbuffered physiological saline at slightly acidic pH, suitable for safe administration to humans. The hemodynamic effects previously described were mild and transient. Radioactivity dosimetric estimates, to be presented separately, are within NIH and U.S. Food and Drug Administration guidelines.
Conclusions
After injection of [18F]-6-fluorodopamine into anesthetized dogs, PET scanning detected tissue sites of uptake, metabolism, and excretion of the radioactivity; that is, ['8F]-6-fluorodopamine can serve as an imaging agent for visualizing tissue-sympathetic innervation, especially in the heart, and for following the hepatic and renal excretion of circulating catecholamines and their metabolites. Pharmacological studies indicated that [18F]-6 -fluorodopaminederived radioactivity in sympathetically innervated tissues was highly localized to vesicles in sympathetic nerve endings. It is possible that changes in the myocardial time-activity curve during uptake-1 blockade with desipramine could provide an index of uptake-1 activity. The slope of this curve seems to depend on both sympathetically-mediated exocytosis and uptake and retention of axoplasmic catecholamines by sympathetic vesicles. 
